LAUSR

A new triple threat to CLL.

Sign Up to like & get
recommendations!
0 Published in 2018 at "Blood"

DOI: 10.1182/blood-2018-08-870808

Abstract: In this issue of Blood, Rogers et al demonstrate that 3 novel agents approved for chronic lymphocytic leukemia (CLL), ibrutinib, venetoclax, and obinutuzumab, can be safely combined at standard doses to create an active, chemotherapy-free… read more here.

Keywords: threat cll; new triple; triple threat;